Pfizer’s Prevnar 20 May Have Edge Over Merck’s Pneumococcal Vaccine, ACIP Suggests

 
• By Brenda Sandburg
  
Generate a summary of this article
Listen to this article
Beta

CDC advisory committee work group concludes benefits of Merck’s PVC15 in those 65 and older is small while benefits of Pfizer’s PVC20 in those 50 and older is large and in those 65 and older is moderate to large.

Pneumococcal vaccine
CDC advisory committee asseses Pfizer and Merck pneumococcal vaccines • Source: Alamy

The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is to vote on recommendations on the routine use of Pfizer Inc.’s 20-valent and Merck & Co., Inc.’s pending 15-valent pneumococcal conjugate vaccines in older adults at its meeting in October. But an analysis presented at ACIP’s 25 June virtual meeting indicates Pfizer's vaccine may have a bigger benefit.

CDC’s Miwako Kobayashi presented ACIP’s evidence-to-benefit framework for use of Pfizer’s PCV20 (Prevnar 20) in those ≥50 and those ≥65...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered. 

EU Filings Tracker TEST

New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Global Pharma Guidance Tracker – August 2024

 
• By Vibha Sharma

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.